JAMES XUE , Ph.D. , M.B.A.
FOUNDER , CHAIRMAN AND CEO
Dr. James Xue is a veteran entrepreneur with extensive experience spans from US to China and from small biotech to multi-national biopharmaceutical companies. Over the last two decades, Dr. Xue led or was involved in several start-up companies and situations as well as managed sizable business and operations that contributed to his unique insight and deep knowledge in the biotech industry.
Dr. Xue built his biotech career by working for some of world’s most innovative companies in the San Francisco Bay Area and the Boston Area. Prior to CANbridge, he was a senior executive at Genzyme where he spent 10 years in various managerial positions with increasing responsibilities. For five years he was founding general manager of Genzyme China during which he managed the launch of several life-saving drugs for the treatment of hematologic cancer and rare metabolic diseases in China including Thymoglobuline® and Cerezyme®. Dr. Xue was recognized as a distinguished expert entrepreneur by the “the Recruitment Program of Global Experts”.
Dr. Xue holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He received executive training from INSEAD and Wharton Business School. Dr. Xue is a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.
BEN WU , M.B.A.
HEAD OF RARE DISEASE BUSINESS
Ben is the Head of Rare Disease Business at CANbridge focusing on making orphan drugs available and accessible to patients with rare diseases in China through an innovative commercial platform.
Mr. Wu has over twenty years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region. Mr. Wu first joined Genzyme in 2008 to pioneer the company’s efforts in expanding its rare disease business into Hong Kong, followed by general management positions covering Southeast Asia, Taiwan and China.
Mr. Wu has a deep knowledge in the orphan drug markets and a strong network among the rare disease communities in Asia. Prior to joining Genzyme, Mr. Wu spent over 14 years at Johnson & Johnson where he held local and regional leadership positions with increasing responsibilities.
Mr. Wu has a Bachelor degree in Pharmaceutical Sciences and an MBA from the University of British Columbia in Canada.
VICE PRESIDENT OF CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS
Dr. Annie Teng has a strong background in oncology and rare disease. Most recently, she was Head of Biology & Early Development at Sanofi, after having served for six years as Medical Director, Specialty Care, there. Prior to Sanofi, she was at Bristol-Meyer-Squibb China, where she was Disease Area Head for Oncology and Immunology. Dr. Teng also spent time in oncology at Pfizer & Pharmacia (later acquired by Pfizer), and started her medical career in pediatrics, focusing on hematology, at Chinese PLA Hospital for 11 years.
Dr. Teng earned her Medical and Master’s degree in Pediatric Medicine from China Medical University. Dr. Teng has also received multiple workplace awards throughout her career, including: China R&D President Award and China Medical Golden Award, both from Sanofi, and the President’s Special Award and Asia-Pacific Award, from BMS.
VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY
Ms. Zhang brings to the position considerable regulatory experience in China in oncology and rare diseases. Prior to join CANbridge, she was the Head of Regulatory Affairs at Novartis Oncology China, where she focused on hematology, solid tumors, and rare diseases. Under her leadership, Novartis Oncology secured six New Drug Applications (NDA) from the China FDA (CFDA). Additionally, Ms. Zhang provided regulatory support for the maintenance and growth of 15 oncology products, and grew the team from 5 to 14 people. She was also a key contributor to the Novartis oncology pipeline development and regulatory strategy in China. From 2012 to 2017, Ms. Zhang served on the R&D-based Pharmaceutical Association Committee (RDPAC), a key Chinese pharmaceutical industry association, as Chair of the Orphan Drug Task Force, where she worked closely with the CFDA on regulation development for orphan drugs. In 2015 and 2017, Ms. Zhang was a speaker at China Rare Disease Summit.
Prior to Novartis, Ms. Zhang was Associate Director of Regulatory Affairs at Genzyme China, where she is the head of the regulatory affairs and focused on rare diseases. Before then, she worked in regulatory affairs at several companies, including Shanghai Roche and Sanofi China. Ms. Zhang started her career as a researcher in the Department of Pharmaceutical Analysis, National Institutes of Pharmaceutical Research & Development, SFDA.
Ms. Zhang holds a MA in Clinical Pharmacology from Hebei Medical University in Shijiazhuang city, China, and a BS in Pharmaceutics from China Pharmaceutical University, in Nanjing, China. She is also a licensed pharmacist.
VICE PRESIDENT OF CHINA ONCOLOGY AND BU HEAD
Fangzhou Cheng brings to CANbridge 18 years of oncology sales and marketing and commercial management experiences. Prior to CANbridge, Fangzhou was with Celgene China (later acquired by BeiGene) where she served as Senior Director and Oncology BU Head of Abraxane for five years. Under Fangzhou’s leadership the Abraxane team grew up to 70 people and achieved over 10% compounded top line growth and annual revenue close to 400M RMB. Post BeiGene merger Fangzhou acted as a core member of China Management team and provided leadership to key company projects including M&A and new product planning.
Before Celgene, Fangzhou was Sales Director at Pfizer China for 3.5 years and was responsible for all oncology products including Sutent and Xalkori. She managed a team of 135 people and sales revenue of 300M RMB and achieved 30% compounded growth rate. Before Pfizer, Fangzhou was with AstraZeneca China where she held a number of oncology sales and marketing positions with increasing responsibilities including Marketing Manager of Iressa.
Fangzhou holds a Bachelor’s Degree of Clinical Medicine from Shanghai University of Traditional Chinese Medicine.
VICE PRESIDENT OF FINANCE AND CONTROLLER
Jeff brings with him 23 years of extensive experience in pharmaceutical finance management and operations. Prior to joining CANbridge, he was with Sanofi China for 5 years and most recently Senior Director, Head of Business Controlling, China Pharma & CHC at Sanofi China. His responsibilities covered 6 BUs with combined revenues of 2 billion euros and a team with 20 staffs. Between 2013 and 2016, He was Pharma Controlling Director and responsible for P&L and OPEX driven financial performance, operations, planning, budgeting, forecasting and reporting, control and compliance. As the China pharma finance lead with a team of 15 staffs, Jeff partnered with country GM and BU heads，implemented systems and processes to ensure business growth and provided decision support. Prior to Sanofi, Jeff built his solid career in pharmaceutical finance at GSK for almost 18 years. He started as Assistant Account at Glaxo Wellcome (which became GSK after the merger between Glaxo Wellcome and SmithKline Beechem in 2001) Hong Kong in 1995. Over the years he progressed his career in financial accounting, FP&A, reporting and operations with increasing responsibilities spanning from GSK Hong Kong to GSK China. His last role at GSK was Senior Finance Manager for GSK China, where he led the Finance Business Partner Team and supported 6 Rx Business Units and Hong Kong with combined revenues of around 800M euros in 2012.
Jeff holds a bachelor’s degree in Business Administration with a major in Accounting from University of Wisconsin, Madison in the U.S. He is also a Certified Public Accountant (Member of AICPA and HKICPA).
SENIOR DIRECTOR OF HUMAN RESOURCES
Chris has over 17 years of bio-pharmaceutical experience in HR management in an all-round way, including 11 years of professional experience in Human Resource Management of a US listed company. Prior to joining CANbridge, Chris held several HR management positions at Sinovac Biotech Ltd. (Nasdaq GSM: SVA) , she has rich experience on recruiting , and in charge of other important HR functions. During those 11 years, staff member increased from 25 to more than 600. Sinovac developed from one single company to a Group, with several subsidiary companies and JV companies. Prior to CANbridge, Chris was the HR Director of Huadu Biotech Ltd.
Chris graduated with a Master Degree in Human Resource Management from RenMin University of China.
MICHAEL J. GLYNN, M.B.A.
Mike Glynn is a seasoned global executive with over 40 years of general management and commercialization experience in Asia Pacific, Japan, Middle East, Latin America and the United States. He has an impressive track record in start-up, turnaround, rapid growth, and organizational development situations.
His employment experience includes three years as SVP Global Commercial Operations at Synageva prior to its acquisition by Alexion; one year as EVP and Chief Commercial Officer at Pacific Biosciences; five years as SVP and Regional President Japan and Asia Pacific at Genzyme; seven years at Boston Scientific, two as Division President of Endovations, one as VP and General Manager Asia, Middle East and Turkey, and four as VP and General Manager Asia Pacific. Earlier in his career he spent 10 years at Baxter International in various functional management roles in Australia and the United States.
At Genzyme, Mike was responsible for the overall P & L and direction of Genzyme’s business in Japan-Asia Pacific with over $500 million in sales and over 600 employees. Revenues grew from $186 million in 2007 to just over $500 million in 2011 with a similar growth in profits. At Boston Scientific he was responsible for approximately $200 million in sales and 420 employees in Asia. During his tenure sales increased at a compounded annual growth rate of just over 30% and operating income increased at a CAGR of 182%.
Mike has a MBA from Macquarie University, Australia and a B.Sc. and Diploma in Education from the National University of Ireland.
Mr. Geraghty is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) program, under which the company supported innovative development programs on a non-commercial basis. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Pieris Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company.
A graduate of the Yale Law School, Mr. Geraghty holds a M.S. from the University of Pennsylvania and a B.A. from Georgetown University.
Iain Baird has worked in the pharmaceutical industry for 29 years. He started work for ICI which later became Zeneca and then AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2003 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees’. In 2006 Iain was one of the principles that established Avecia Vaccines in which he led the manufacturing and supply groups in the development of vaccines against anthrax and plague.
Since 2010 Iain has been an independent consultant assisting clients in the development of their clinical products and has been involved in 3 successful BLA applications and 3 NDA applications as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections, preparing them for the inspections, supporting them during the inspections and in their successful responses.
Iain specializes in working with the founders/CEO’s of companies with innovative products and services and has been working with CANbridge CEO James Xue since the start of 2013 assisting in the evaluation of product candidates that could be developed in the Chinese market. During that time, Iain has also worked with the founder of Gallus in the negotiation and establishment of Gallus Biopharmaceuticals, a pure play CDMO, and subsequently has worked with the founder of Brammer Bio for the development and manufacturing of viral vectors.
XIAOPING YE , M.D. , Ph.D.
Founder, President of Tigermed, M.D., Ph.D., E.M.B.A.
EMBA of Guanghua School of Management, Peking University, obtained PhD in Oxford University UK.
Over 10 years’ experience in medical and regulatory affairs with global pharmaceutical industries.
The Former medical director in Shanghai Roche for 6 years.
MARK GOLDBERG , M.D.
Dr. Goldberg joined CANbridge as Acting Chief Medical Officer in 2015. He has been a member of the company's Advisory Board since 2013. Dr. Goldberg brings to CANbridge over 30 years of clinical and industry experience as a seasoned oncologist, hematologist and corporate medical/regulatory strategist.
Prior to CANbridge, he was Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation. Dr. Goldberg joined Synageva in 2011 from Genzyme Corporation, where he had most recently served as Senior Vice President, Clinical Development and Global Therapeutic Group Head, Oncology and Personalized Genetic Health. While at Genzyme, he played a central role in the development and approval of medicines such as Fabrazyme®, Aldurazyme®, Myozyme®, Lumizyme®, and Mozobil®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute. He holds appointments at Brigham and Women's Hospital and Dana Farber Cancer Institute and is also an Associate Professor of Medicine (part time) at Harvard Medical School.
Dr. Goldberg received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School. He holds Board appointments at Immunogen Corporation, Idera Pharmaceuticals, Glycomimetics, aTyr Pharma, Blueprint Medicines, and the American Cancer Society, New England Division.